Publication CONNEXION Selected to Present at the 45th Annual Drug Information Association Meeting in... ( NEWTOWN Pa. April 20 /- The managing ...)

Publication CONNEXION Selected to Present at the 45th Annual Drug Information Association Meeting in San Diego

Date:4/20/2009

NEWTOWN, Pa., April 20 /PRNewswire/ -- The managing director of Publication CONNEXION, a CONNEXION Healthcare Company, has been invited to speak at the 45th Annual Drug Information Association (DIA) Meeting, in San Diego.

Henry W. Singer will be present a talk entitled "Effective Publication Practices" (Abstract number 25205) on Tuesday, June 23, 2009.

DIA is a pharmaceutical industry five-day summit uniting professionals from all facets within the industry.

Following his presentation, Singer will participate in a panel discussion on publication planning. Co-panelists include representatives from Beardsworth, Elsevier, and Eli Lilly.

"I'm very enthusiastic about the opportunity to present on best practices in academic publication planning," Singer said. "Transparent, compliant and medical-need driven publications define our processes at PCX, and the opportunity to discuss these issues is important and timely."

Newtown, PA-based CONNEXION Healthcare is a full-service healthcare communications company specializing in professional and promotional medical education.

SOURCE CONNEXION Healthcare
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Post Your Comments:

(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus

(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in

(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju

(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F

(Date:12/4/2009)Dr. Redlener Applauds Historic Effort but Points out Potential Risk if America,s Safety Net Programs Are Lost in Final Health Care Reform ,, NEW YORK, Dec. 4 The New England Journal of Medicine

Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2 Health News:Are angry women more like men? 2 Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2 Health News:Makers of Powerful Painkillers Present Safety Plans 2 Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2

[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Are angry women more like men?[0] Timing of Multiple-Ligament Knee Surgery May Not Matter [0] Makers of Powerful Painkillers Present Safety Plans [0] New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform

...tudies on the use of stem cells for cardiac repair...ing of the Heart Failure Association of the Europe...mish-Partenkirchen, Germany. Findings in experime...Over one hundred top cardiologists from all over E...

... walk a few days a week cut death risk in half, st...y News) -- Even a moderate amount of exercise can...n middle-aged and elderly American veterans reveal...ays a week was enough to halve the risk of prematu...

...arnings teleconference today at 10:00 a.m. EST by ...01417, or listen on the Web at: http://www.ai...s.htm ., LEHIGH VALLEY, Pa., Jan. 23 Air Product...1,2007. Net income increased 15 percent, and dilut...

...l,s Success at European Patent Hearing is Confirme... EDINBURGH, Scotland, January 23 The European Pa...tent (the ,131, patent) not,valid as granted. In a...announcing the EPO ruling as a success, despite th...

...t Be Offered Advanced Therapy, HOLLYWOOD, Fla., J...ke treatment using clot-busting drugs may succeed ...ts directly in the brain, according,to data being ...IV),stroke therapy aren,t given the chance to succ...

.... 22 Today,s USA Today,features a major story in ...new book telling the stories of more than 40 organ...holas Green, who was a 7-year-old boy killed,durin...onors., However, nearly 100,000 Americans are cur...

Stem cells could be used for cardiac repair A Little Regular Exercise Extends Men's Lives Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance Aircraft Medical: European Patent Hearing Stroke Undertreated Organ Donor/Recipient Interviews

(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d

(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed

[0] PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop [0] PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop [0] Watson Files FDA Application for Generic Rozerem(R)

... Nastech Pharmaceutical,Company Inc. (Nasdaq: NS...al,trial evaluating the Company,s PYY3-36 Nasal Sp...ximately 500 obese patients for a six-month,random...eight loss as the,primary endpoint. The Phase 2 s...,Nastech,s PYY3-36 Nasal Spray compared to placebo...

.... 1 Sanofi-aventis,announced that the U.S. Food a...(R) (docetaxel) Injection Concentrate in combinati... therapy of locally advanced squamous cell,carcino...dergo,chemoradiotherapy and surgery. The FDA base...domized,open-label, international trial, TAX 324, ...

Other Medicine Technology:Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity 2 Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity 3 Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 2 Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 3 Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 4

Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

Woodlyn Refractor

Illuminated Phoroptor

Ultramatic RX Master PHOROPTOR Refracting Instrument - Minus Cylinder Black

Red Lens Maddox

Medicine Products:

Woodlyn Refractor Illuminated Phoroptor Ultramatic RX Master PHOROPTOR Refracting Instrument - Minus Cylinder Black Red Lens Maddox

Publication CONNEXION Selected to Present at the 45th Annual Drug Information Association Meeting in...( NEWTOWN Pa. April 20 /- The managing ...),Health